Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shaji Kumar

Showing results (111-120 of 515) with videos related to

Pageof 52
Sort By:
British Journal of Haematology|February 22, 2020
Mass cytometry identifies expansion of double positive and exhausted T cell subsets in the tumour microenvironment of patients with POEMS syndromeTaxiarchis V Kourelis, Dragan Jevremovic, Erik Jessen, et al.
Blood Cancer Journal|August 30, 2019
Mass cytometry dissects T cell heterogeneity in the immune tumor microenvironment of common dysproteinemias at diagnosis and after first line therapiesTaxiarchis V Kourelis, Jose C Villasboas, Erik Jessen, et al.
Research Square|February 27, 2026
Metabolic Heterogeneity and Niche Rewiring in Plasma Cells are Associated with Progression from MGUS to Multiple MyelomaAxel Walch, Guoxing Zhang, Na Sun, et al.
Blood|July 31, 2009
Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2Mamta Gupta, Stephen M Ansell, Anne J Novak, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 26, 2025
Treatment Patterns and Clinical Outcomes of Patients With Systemic Light Chain Amyloidosis in the United States: Evidence From Real-World Clinical PracticeSophia S Li, Anita D'Souza, Suzanne Lentzsch, et al.
British Journal of Haematology|September 26, 2015
A Phase Ib Study of the combination of the Aurora Kinase Inhibitor Alisertib (MLN8237) and Bortezomib in Relapsed Multiple MyelomaAllison Rosenthal, Shaji Kumar, Craig Hofmeister, et al.
Plos One|November 28, 2012
Anti-myeloma activity of Akt inhibition is linked to the activation status of PI3K/Akt and MEK/ERK pathwayVijay Ramakrishnan, Teresa Kimlinger, Jessica Haug, et al.
Mayo Clinic Proceedings|September 19, 2020
Rapid Appraisal System for COVID-19 Medical InformationRaymund R Razonable, William F Marshall, Ryan W Stevens, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|October 16, 2025
A collaborative approach to amyloidosis and a multidisciplinary care framework - position statement from the International Society of AmyloidosisVaishali Sanchorawala, Ashutosh Wechalekar, Peter Mollee, et al.
Nucleic Acids Research|December 31, 2005
ProTherm and ProNIT: thermodynamic databases for proteins and protein-nucleic acid interactionsM D Shaji Kumar, K Abdulla Bava, M Michael Gromiha, et al.
Pageof 52

Showing results (111-120 of 515) with videos related to

Sort By:
Pageof 52
British Journal of Haematology|February 22, 2020
Mass cytometry identifies expansion of double positive and exhausted T cell subsets in the tumour microenvironment of patients with POEMS syndromeTaxiarchis V Kourelis, Dragan Jevremovic, Erik Jessen, et al.
Blood Cancer Journal|August 30, 2019
Mass cytometry dissects T cell heterogeneity in the immune tumor microenvironment of common dysproteinemias at diagnosis and after first line therapiesTaxiarchis V Kourelis, Jose C Villasboas, Erik Jessen, et al.
Research Square|February 27, 2026
Metabolic Heterogeneity and Niche Rewiring in Plasma Cells are Associated with Progression from MGUS to Multiple MyelomaAxel Walch, Guoxing Zhang, Na Sun, et al.
Blood|July 31, 2009
Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2Mamta Gupta, Stephen M Ansell, Anne J Novak, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 26, 2025
Treatment Patterns and Clinical Outcomes of Patients With Systemic Light Chain Amyloidosis in the United States: Evidence From Real-World Clinical PracticeSophia S Li, Anita D'Souza, Suzanne Lentzsch, et al.
British Journal of Haematology|September 26, 2015
A Phase Ib Study of the combination of the Aurora Kinase Inhibitor Alisertib (MLN8237) and Bortezomib in Relapsed Multiple MyelomaAllison Rosenthal, Shaji Kumar, Craig Hofmeister, et al.
Plos One|November 28, 2012
Anti-myeloma activity of Akt inhibition is linked to the activation status of PI3K/Akt and MEK/ERK pathwayVijay Ramakrishnan, Teresa Kimlinger, Jessica Haug, et al.
Mayo Clinic Proceedings|September 19, 2020
Rapid Appraisal System for COVID-19 Medical InformationRaymund R Razonable, William F Marshall, Ryan W Stevens, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|October 16, 2025
A collaborative approach to amyloidosis and a multidisciplinary care framework - position statement from the International Society of AmyloidosisVaishali Sanchorawala, Ashutosh Wechalekar, Peter Mollee, et al.
Nucleic Acids Research|December 31, 2005
ProTherm and ProNIT: thermodynamic databases for proteins and protein-nucleic acid interactionsM D Shaji Kumar, K Abdulla Bava, M Michael Gromiha, et al.
Pageof 52